JP2005225888A5 - - Google Patents

Download PDF

Info

Publication number
JP2005225888A5
JP2005225888A5 JP2005085060A JP2005085060A JP2005225888A5 JP 2005225888 A5 JP2005225888 A5 JP 2005225888A5 JP 2005085060 A JP2005085060 A JP 2005085060A JP 2005085060 A JP2005085060 A JP 2005085060A JP 2005225888 A5 JP2005225888 A5 JP 2005225888A5
Authority
JP
Japan
Prior art keywords
vector
administration
interferon
cancer
viral vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2005085060A
Other languages
English (en)
Japanese (ja)
Other versions
JP4219335B2 (ja
JP2005225888A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2005225888A publication Critical patent/JP2005225888A/ja
Publication of JP2005225888A5 publication Critical patent/JP2005225888A5/ja
Application granted granted Critical
Publication of JP4219335B2 publication Critical patent/JP4219335B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2005085060A 1997-08-29 2005-03-23 インターフェロンβのような分泌タンパク質をコードする遺伝子を使用する治療のための方法および組成物 Expired - Fee Related JP4219335B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5725497P 1997-08-29 1997-08-29

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2003412621A Division JP3953458B2 (ja) 1997-08-29 2003-12-10 インターフェロンβのような分泌タンパク質をコードする遺伝子を使用する治療のための方法および組成物

Publications (3)

Publication Number Publication Date
JP2005225888A JP2005225888A (ja) 2005-08-25
JP2005225888A5 true JP2005225888A5 (https=) 2006-12-14
JP4219335B2 JP4219335B2 (ja) 2009-02-04

Family

ID=22009467

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2000507824A Expired - Fee Related JP4124565B2 (ja) 1997-08-29 1998-08-25 インターフェロンβのような分泌タンパク質をコードする遺伝子を使用する治療のための方法および組成物
JP2003412621A Expired - Fee Related JP3953458B2 (ja) 1997-08-29 2003-12-10 インターフェロンβのような分泌タンパク質をコードする遺伝子を使用する治療のための方法および組成物
JP2005085060A Expired - Fee Related JP4219335B2 (ja) 1997-08-29 2005-03-23 インターフェロンβのような分泌タンパク質をコードする遺伝子を使用する治療のための方法および組成物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2000507824A Expired - Fee Related JP4124565B2 (ja) 1997-08-29 1998-08-25 インターフェロンβのような分泌タンパク質をコードする遺伝子を使用する治療のための方法および組成物
JP2003412621A Expired - Fee Related JP3953458B2 (ja) 1997-08-29 2003-12-10 インターフェロンβのような分泌タンパク質をコードする遺伝子を使用する治療のための方法および組成物

Country Status (24)

Country Link
EP (1) EP1007717B8 (https=)
JP (3) JP4124565B2 (https=)
KR (1) KR100699285B1 (https=)
CN (1) CN100342019C (https=)
AT (1) ATE316145T1 (https=)
AU (1) AU740428B2 (https=)
BR (1) BR9812138A (https=)
CA (1) CA2300480C (https=)
CY (1) CY1105029T1 (https=)
CZ (2) CZ297314B6 (https=)
DE (1) DE69833264T2 (https=)
DK (1) DK1007717T3 (https=)
EA (1) EA003256B1 (https=)
EE (1) EE04873B1 (https=)
ES (1) ES2257817T3 (https=)
HU (1) HU224422B1 (https=)
IL (2) IL134593A0 (https=)
IS (1) IS2318B (https=)
NO (1) NO20000990L (https=)
NZ (1) NZ503401A (https=)
PT (1) PT1007717E (https=)
SK (1) SK286821B6 (https=)
TR (1) TR200000532T2 (https=)
WO (1) WO1999010516A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE357935T1 (de) 2001-01-22 2007-04-15 Biogen Idec Inc Verfahren zum erhöhen der zuführung einer therapeutischen nukleinsäure
US8058248B2 (en) * 2001-04-26 2011-11-15 The United States Of America As Represented By The Secretary Of Agriculture Foot and mouth disease virus vaccine comprising interferons
CN1388248A (zh) * 2001-05-25 2003-01-01 钱其军 高效表达干扰素的肿瘤细胞内特异性增殖的腺病毒及其构建方法
EP1835032A1 (en) * 2006-03-14 2007-09-19 Université de Liège A self-inactivating recombinant lentiviral vector for the inhibition of HIV replication
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
CN103505722B (zh) * 2012-06-19 2016-04-13 苏州丁孚靶点生物技术有限公司 干扰素在治疗/预防对常规抗肿瘤疗法有抗性的肿瘤中的用途及相关的产品和方法
US20190125804A1 (en) * 2016-06-15 2019-05-02 Tissue Regeneration Therapeutics Inc. Anti-cancer use of genetically modified human umbilical cord perivascular cells (hucpvc)
JP7644722B2 (ja) * 2019-06-01 2025-03-12 シベック バイオテクノロジーズ，インコーポレイティド 真核細胞への遺伝子編集システムの送達のための細菌プラットフォーム

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2122519C (en) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
EP1369487A3 (en) * 1994-08-16 2004-04-07 Crucell Holland B.V. Recombinant vectors derived from adenovirus for use in gene therapy
US5952221A (en) * 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence

Similar Documents

Publication Publication Date Title
Hervas-Stubbs et al. Direct effects of type I interferons on cells of the immune system
Higashi et al. A novel cancer vaccine strategy with combined IL-18 and HSV-TK gene therapy driven by the hTERT promoter in a murine colorectal cancer model
Bui et al. In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2
JP2005225888A5 (https=)
Yaghchi et al. Vaccinia virus, a promising new therapeutic agent for pancreatic cancer
JP2018139586A5 (https=)
Wang et al. Combined IL-12 and GM-CSF gene therapy for murine hepatocellular carcinoma
Wang et al. Survivin promoter-regulated oncolytic adenovirus with Hsp70 gene exerts effective antitumor efficacy in gastric cancer immunotherapy
JP2004525855A5 (https=)
JP2013516454A5 (https=)
JP2016128507A5 (https=)
Ren et al. Co-expression of ING4 and P53 enhances hypopharyngeal cancer chemosensitivity to cisplatin in vivo
Wang et al. Adenovirus-mediated Il-24 expression suppresses hepatocellular carcinoma growth via induction of cell apoptosis and cycling arrest and reduction of angiogenesis
KR20210005637A (ko) 종양 치료용 콕삭키바이러스 b
JP2006511212A5 (https=)
Sun et al. Genetically engineered recombinant adenovirus expressing interleukin‑2 for hepatocellular carcinoma therapy
ES2257817T3 (es) Metodos y composiciones para terapias contra el cancer utilizando genes codificantes de interferon-beta.
Gao et al. Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA
Wang et al. Tuning the molecular size of site-specific interferon-polymer conjugate for optimized antitumor efficacy
Lin et al. Combination of DESI2 and IP10 gene therapy significantly improves therapeutic efficacy against murine carcinoma
Marukawa et al. Membrane-bound form of monocyte chemoattractant protein-1 enhances antitumor effects of suicide gene therapy in a model of hepatocellular carcinoma
Akbulut et al. Antitumor immune response induced by it injection of vector-activated dendritic cells and chemotherapy suppresses metastatic breast cancer
US12121554B2 (en) Materials and methods for treatment with oncolytic viruses and modified CAR T cells
Guo et al. Recombinant adenovirus expressing a dendritic cell-targeted melanoma surface antigen for tumor-specific immunotherapy in melanoma mice model
JP2008523067A5 (https=)